J. P. Olié, Les effets indésirables des neuroleptiques, 1990.

D. Ginestet, Guide du bon usage des psychotropes, 1997.

J. Delay and P. Deniker, Utilisation thérapeutique psychiatrique d'une phénothiazine d'action centrale élective, 4560RP psychol, vol.110, pp.112-119, 1952.

J. Flamand-villeneuve, « Les perturbations métaboliques liées à la prise d'antipsychotiques de seconde génération : revue de littérature et prise en charge

E. Richelson, Preclinical pharmacology of neuroleptics: focus on new generation compounds, J Clin Psychiatry, vol.57, issue.suppl11, pp.4-11, 1996.

B. Green, Focus on Quetiapine, Current Medical Research and Opinion, vol.15, issue.3, pp.145-51, 1999.
DOI : 10.1185/03007999909114085

D. Copolov, C. Link, and B. Kowalcyk, A multicentre, double-blind, randomized comparison of quetiapine (ICI 204

J. Peuskens and C. Link, A comparison of quetiapine and chlorpromazine in the treatment of schizophrenia, Acta Psychiatrica Scandinavica, vol.45, issue.4, pp.265-73, 1997.
DOI : 10.1016/0149-2918(95)80102-2

R. Keller and F. Mongini, Switch to quetiapine in antipsychotic agent-related hyperprolactinemia, Neurological Sciences, vol.23, issue.5, pp.233-238, 2002.
DOI : 10.1007/s100720200047

V. Simon, R. Van-winkel, D. Hert, and M. , Are Weight Gain and Metabolic Side Effects of Atypical Antipsychotics Dose Dependent?, The Journal of Clinical Psychiatry, vol.70, issue.7, pp.1041-50, 2009.
DOI : 10.4088/JCP.08r04392

S. Cheer, A. Wagstaff, and . Quetiapine, Quetiapine, CNS Drugs, vol.16, issue.4, pp.173-99, 2004.
DOI : 10.2165/00023210-200418030-00004

D. Copolov, C. Link, and B. Kowalcyk, A multicentre, double-blind, randomized comparison of quetiapine (ICI 204

J. Peuskens and C. Link, A comparison of quetiapine and chlorpromazine in the treatment of schizophrenia, Acta Psychiatrica Scandinavica, vol.45, issue.4, pp.265-73, 1997.
DOI : 10.1016/0149-2918(95)80102-2

R. Keller and F. Mongini, Switch to quetiapine in antipsychotic agent-related hyperprolactinemia, Neurological Sciences, vol.23, issue.5, pp.233-238, 2002.
DOI : 10.1007/s100720200047

J. Newcomer, Metabolic considerations in the use of antipsychotic medications: a review of recent evidence, J Clin Psychiatry, vol.68, issue.1, pp.20-27, 2007.

J. Newcomer and D. Haupt, The Metabolic Effects of Antipsychotic Medications, The Canadian Journal of Psychiatry, vol.62, issue.8, pp.480-91, 2006.
DOI : 10.1176/appi.ajp.160.9.1651

J. Horacek, V. Bubenikova-valesova, M. Kopecek, T. Palenicek, C. Dockery et al., Mechanism of Action of Atypical Antipsychotic Drugs and the Neurobiology of Schizophrenia, CNS Drugs, vol.181, issue.2, pp.389-409, 2006.
DOI : 10.2165/00023210-200620050-00004

H. Meltzer, S. Matsubara, and J. Lee, Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values, J Pharmacol Exp Ther, vol.251, issue.1, pp.238-284, 1989.

S. Cheer, A. Wagstaff, and . Quetiapine, Quetiapine, CNS Drugs, vol.16, issue.4, pp.173-99, 2004.
DOI : 10.2165/00023210-200418030-00004

S. Kapur, R. A. Mcclelland, and S. C. Vanderspek, Increasing D2 affinity results in the loss of clozapine??s atypical antipsychotic action, Neuroreport, vol.13, issue.6, pp.831-835, 2002.
DOI : 10.1097/00001756-200205070-00019

S. Bakchine and M. Habert, Classification des d??mences??: aspects nosologiques, M??decine Nucl??aire, vol.31, issue.6, pp.278-307, 2007.
DOI : 10.1016/j.mednuc.2007.04.005

G. Micieli, Vascular dementia, Neurological Sciences, vol.27, issue.S1, pp.37-46, 2006.
DOI : 10.1007/s10072-006-0545-7

J. De-la-torre, Alzheimer Disease as a Vascular Disorder: Nosological Evidence, Stroke, vol.33, issue.4
DOI : 10.1161/01.STR.0000014421.15948.67

J. Zaccai, C. Mccracken, and C. Brayne, A systematic review of prevalence and incidence studies of dementia with Lewy bodies, Age and Ageing, vol.34, issue.6, pp.561-567, 2005.
DOI : 10.1093/ageing/afi190

I. Mckeith, E. Perry, and D. Aarsland, Differences in neuropathologic characteristics across the Lewy body dementia spectrum, Neurology, vol.67, issue.11, pp.1931-1935, 2006.

I. Mckeith, Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): Report of the Consortium on DLB International Workshop, Journal of Alzheimer's Disease, vol.9, issue.s3, pp.417-440, 2006.
DOI : 10.3233/JAD-2006-9S347

D. Aarsland, R. Perry, A. Brown, J. Larsen, and C. Ballard, Neuropathology of dementia in Parkinson's disease: A prospective, community-based study, Annals of Neurology, vol.100, issue.5, pp.773-779, 2005.
DOI : 10.1002/ana.20635

C. Duyckaerts, Nosologie des d??mences. Le point de vue du neuropathologiste, Revue Neurologique, vol.162, issue.10, pp.921-929, 2006.
DOI : 10.1016/S0035-3787(06)75101-3

P. Voyer, Soins infirmiers aux aînés en perte d'autonomie : une approche adaptée au CHSLD. Chapitre 2 Les démences, pp.15-20, 2006.

E. Colerick and L. George, Predictors of Institutionalization Among Caregivers of Patients With Alzheimer's Disease, Journal of the American Geriatrics Society, vol.25, issue.7, pp.492-498, 1986.
DOI : 10.1111/j.1532-5415.1986.tb04239.x

P. Gibert, J. Malot, and G. Gavazzi, Guide de prescription chez les personnes âgées

S. Léger and I. D. , un programme d'éducation d es patients sous traitement anti-vitamine K sur les attitudes de prévention vis à vis, 2002.

S. Ferchichi and V. Antoine, Le bon usage des m??dicaments chez la personne ??g??e, La Revue de M??decine Interne, vol.25, issue.8, pp.582-90, 2004.
DOI : 10.1016/j.revmed.2004.02.027

G. Onder, F. Landi, M. Cesari, G. Gambassi, P. Carbonin et al., Inappropriate medication use among hospitalized older adults in Italy: results from the Italian Group of Pharmacoepidemiology in the Elderly, European Journal of Clinical Pharmacology, vol.279, issue.2, pp.157-62, 2003.
DOI : 10.1001/jama.279.23.1877

K. Schmader, Unnecessary drug use in frail older people at hospital discharge, J Am Geriatr Soc, vol.53, issue.9, pp.1518-1541, 2005.

J. Gurwitz, T. Field, J. Avorn, D. Mccormick, S. Jain et al., Incidence and preventability of adverse drug events in nursing homes, The American Journal of Medicine, vol.109, issue.2, pp.87-94, 2000.
DOI : 10.1016/S0002-9343(00)00451-4

D. Fick, J. Cooper, W. Wade, J. Waller, J. Maclean et al., Updating the Beers Criteria for Potentially Inappropriate Medication Use in Older Adults, Archives of Internal Medicine, vol.163, issue.22, pp.2716-2740, 2003.
DOI : 10.1001/archinte.163.22.2716

M. Steinman, G. Rosenthal, C. Landefeld, D. Bertenthal, and P. Kaboli, Agreement Between Drugs-to-Avoid Criteria and Expert Assessments of Problematic Prescribing, Archives of Internal Medicine, vol.169, issue.14, pp.1326-1358, 2009.
DOI : 10.1001/archinternmed.2009.206

P. Mcleod, A. Huang, R. Tamblyn, and D. Gayton, Defining inappropriate practices in prescribing for elderly people: a national consensus panel, CMAJ. Feb CMAJ. Feb, vol.1156156, issue.13, pp.385-91385, 1997.

C. Naugler, C. Brymer, P. Stolee, and Z. Arcese, Development and validation of an improving prescribing in the elderly tool, Can J Clin Pharmacol. Summer, vol.7, issue.2, pp.103-110, 2000.

M. Laroche, J. Charmes, and M. L. , Potentially inappropriate medications in the elderly: a French consensus panel list, European Journal of Clinical Pharmacology, vol.23, issue.8, pp.725-756, 2007.
DOI : 10.1007/s00228-007-0324-2

M. Steinman, G. Rosenthal, C. Landefeld, D. Bertenthal, S. Sen et al., Conflicts and concordance between measures of medication prescribing quality. Med Care, pp.95-104, 2007.

M. Steinman, G. Rosenthal, C. Landefeld, D. Bertenthal, and P. Kaboli, Agreement Between Drugs-to-Avoid Criteria and Expert Assessments of Problematic Prescribing, Archives of Internal Medicine, vol.169, issue.14, pp.1326-1358, 2009.
DOI : 10.1001/archinternmed.2009.206

G. Paul, M. Shekelle, C. H. Maclean, M. Sally, C. Morton et al., Assessing Care of Vulnerable Elders: Methods for Developing Quality Indicators, Ann Intern Med, vol.135, pp.647-652, 2001.

P. Lang, Y. Hasso, J. Belmin, I. Payot, J. Baeyens et al., START: adaptation of a French language screening tool for detecting inappropriate prescriptions in older people, Can J Public Health, vol.100, issue.6, pp.426-457, 2009.

P. Gallagher, C. Ryan, S. Byrne, J. Kennedy, O. Mahony et al., STOPP (Screening Tool of Older Person??s Prescriptions) and START (Screening Tool to Alert doctors to Right Treatment). Consensus validation, Int. Journal of Clinical Pharmacology and Therapeutics, vol.46, issue.02, pp.72-83, 2008.
DOI : 10.5414/CPP46072

P. Gibert, J. Mallot, J. Calop, and G. Gavazzi, Modalités de prescription des médicaments aux personnes âgées

J. Morris, THE NOSOLOGY OF DEMENTIA, Neurologic Clinics, vol.18, issue.4, pp.773-88, 2000.
DOI : 10.1016/S0733-8619(05)70225-5

J. D. Guelfi, « Critères diagnostiques » American Psychiatric Association, 1996.

J. Bergeron, L. Mallet, and L. «. Papillon-ferland, Principes d'évaluation de la pharmacothérapie en gériatrie : illustration à l'aide d'un cas de patient, pp.11-25, 2008.

D. Larocque and S. Rivest, Toll-like receptor 4 stimulation with the detoxified ligand monophosphoryl lipid A improves Alzheimer's disease-related pathology, Proc Natl Acad Sci, 2013.

B. Winblad, N. Andreasen, L. Minthon, A. Floesser, G. Imbert et al., Safety, tolerability, and antibody response of active A? immunotherapy with CAD106 in patients with

D. Générale-de-la-santé and . France-alzheimer, Association Francophone des Droits de l'Homme Agé (AFDHA) ? Alzheimer, l'éthique en question, p.44

M. Hebert-demay, Prescription de neuroleptiques chez les patients déments : recommandations et réalités pratiques, 2010.